Cellectar Q3 net loss widens to $7.8M; raises $10.7M in October financing

Cellectar Biosciences, Inc.

2022-Q3 EPS reported -$3.50

Net loss Q3 2022: ($7.8M) or ($1.28)/share vs ($5.8M) ($0.97)/share in Q3 2021.
Cash and equivalents $17.8M at Sep 30, 2022, down from $35.7M at Dec 31, 2021.
Closed $10.7M gross proceeds from registered direct and private placement in October.
R&D expense $5.4M (up from $3.9M) driven by Waldenstrom's macroglobulinemia pivotal trial.
Awarded $2M NCI grant to expand Phase 1 pediatric brain tumor trial to Phase 1b.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cellectar Biosciences, Inc. reported third quarter ended September 30, 2022 results: net income ($7.8) million, EPS ($1.28) per share.

Period: third quarter ended September 30, 2022
Net income: ($7.8) million
EPS: ($1.28) per share
Result: reported results

Exact text from the filing

The net loss attributable to common stockholders for the quarter ended September 30, 2022 was ($7.8) million, or ($1.28) per share, compared to ($5.8) million, or ($0.97) per share, in the quarter ended September 30, 2021

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cellectar Biosciences, Inc. reported nine months ended September 30, 2022 results: net income ($21.4) million, EPS ($3.50) per share.

Period: nine months ended September 30, 2022
Net income: ($21.4) million
EPS: ($3.50) per share
Result: reported results

Exact text from the filing

the loss attributable to common stockholders for the nine months ended September 30, 2022 was ($21.4) million, or ($3.50) per share, compared to ($18.2) million, or ($3.39) per share, in 2021

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-114234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.